期刊文献+

替比夫定与拉米夫定长期治疗慢性乙型肝炎的安全性评价 被引量:8

下载PDF
导出
摘要 目的评价替比夫定与拉米夫定长期治疗慢性乙型肝炎的疗效及安全性。方法 2011年2月至2012年2月符合入选39例慢性乙型肝炎患者,分为替比夫定组25例,拉米夫定组25例观察两组临床疗效及安全性。结果替比夫定组完全应答率明显比拉米夫定组更佳,P<0.05,差异有统计学意义;替比夫定组肌酸激酶升高发生率24%,拉米夫定组肌酸激酶升高发生率6%,P<0.05,具有统计学意义。结论替比夫定临床治疗慢性乙型肝炎疗效确切,不良反应少,是一种较为安全的抗乙型肝炎病毒临床药物,可用于一线治疗。
作者 张金霞
出处 《中国医药指南》 2012年第30期150-151,共2页 Guide of China Medicine
  • 相关文献

参考文献3

二级参考文献16

  • 1Anna SF LOK.乙型肝炎病毒耐药性临床需知[J].肝脏,2007,12(1):43-45. 被引量:15
  • 2Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol, 2006, 45(4): 529-538.
  • 3Chan HLY, Sung JJY. Hepatocellular carcinoma and hepatitis B virus. Semin. liver Dis, 2006, 26(2): 153-161.
  • 4Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2007, 45(2): 507-539.
  • 5Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions: version 5.0.1 Cochrane Collaboration, 2008.
  • 6Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology, 2009, 136(2): 486-495.
  • 7Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 2007, 357(25): 2576- 2588.
  • 8Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology, 2008, 47(2): 447-454.
  • 9Jia JD, Hou JL, Yin YK, et al. Two-year results of a phase III comparative trial of telbivudine vs lamivudine in Chinese patients. Journal of Hepatology, 2007, 46 Suppl 1: S189.
  • 10Deepak N Amarapurkar.Telbivudine:A new treatment for chronic hepatitis B[J].World Journal of Gastroenterology,2007,13(46):6150-6155. 被引量:28

共引文献36

同被引文献53

  • 1贾继东,侯金林,尹有宽,徐道振,谭德明,牛俊奇,周霞秋,王宇明,朱理珉,贺永文,任红,万谟彬,陈成伟,巫善明,陈亚岗,许家璋,王勤环,魏来,马红.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J].中华肝脏病杂志,2007,15(5):342-345. 被引量:141
  • 2Chemin I, Zoulim F.Hepatitis B virus induced hepatocel- lular carcinoma. Cancer Lett[J]. Cancer Lett, 2009, 286 (1):52.
  • 3Kumars KS, Byrne G. Some evidence shows that certain mouth rinses can reduce halitosis[J]. J Am Dent Assoc, 2010,141(8) : 1 008.
  • 4Amponsah DE, Lebelo RL, Rakgole JN, et al. Hepatitis b virus infection in post-vaccination south africa: occult HBV infection and circulating surface gene variants [ J ]. Journal of Clinical Virology, 2015,63 : 12 - 17.
  • 5Hu L,Zhai X,Liu J,et al.Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development[J].Hepatology,2012,55(5):1426-1431.
  • 6Sonneveld MJ,Rijckborst V,Zeuzem S,et al.Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B[J].Hepatology,2012,56(1):67-75.
  • 7Ito K,Yotsuyanagi H,Yatsuhashi H,et al.Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults[J].Hepatology,2014,59(1):89-97.
  • 8Yotsuyanagi H,Ito K,Yamada N,et al.High levels of hepatitis B virus after the onset of disease lead to chronic infection in patients with acute hepatitisB[J].Clin Infect Dis,2013,57(7):935-942.
  • 9Zhang Y,Mao R,Yan R,et al.Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection[J].PloS one,2014,9(10):e110442.
  • 10Ogura N,Watashi K,Noguchi T,et al.Formation of covalently closed circular DNA in Hep38.7-Tet cells,a tetracycline inducible hepatitis B virusexpression cell line[J].Biochem Biophys Res Commun,2014,452(3):315-321.

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部